Attorney General Dave Sunday announced that Pennsylvania is part of a $720 million national settlement with eight drug manufacturers accused of contributing to the opioid crisis.
The state could receive up to $28 million, depending on participation from local governments during the settlement’s sign-on period.
The eight companies and their payment obligations are:
- Mylan (now part of Viatris): $284.4 million over nine years
- Hikma: $95.8 million over one to four years
- Amneal: $71.7 million over 10 years
- Apotex: $63.7 million in a single year
- Indivior: $38 million over four years
- Sun: $31 million over one to four years
- Alvogen: $18.7 million in a single year
- Zydus: $14.9 million in a single year
Several settlements also include provisions for free pharmaceutical products or cash alternatives.
Seven of the companies—excluding Indivior—have agreed to cease promoting opioids, stop producing pills with more than 40 mg of oxycodone, and implement systems to monitor suspicious orders. Indivior will not manufacture or sell opioid products for the next 10 years but may continue selling medications to treat opioid use disorder.
This settlement follows a previous $7.4 billion agreement with Purdue Pharma and the Sackler family, which is expected to bring up to $200 million to Pennsylvania.
